Drug intelligence / Profile preview

RG-1671

Development stage: Phase 1
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RG-1671 is a monoclonal antibody developed by F. Hoffmann-La Roche Ltd. that acts as an inhibitor of the interleukin 13 receptor (IL-13R). Its primary mechanism of action is to block IL-13R, thereby modulating immune responses associated with diseases such as asthma. The drug was investigated for use in immune system and respiratory diseases, specifically intermittent asthma. A Phase 1 clinical trial evaluated its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with mild, intermittent asymptomatic asthma via intravenous infusion at escalating doses[1].

Other names: RG-1671RG1671RG 1671

Targets

IL13RA2 (Interleukin-13 receptor subunit alpha 2)

Beyond the preview

Go deeper on RG-1671.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RG-1671.

Explore the full profile